RT Journal Article
SR Electronic
T1 Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1452
OP 1457
DO 10.3899/jrheum.110271
VO 38
IS 7
A1 JASVINDER A. SINGH
A1 WILL J. TAYLOR
A1 LEE S. SIMON
A1 PUJA P. KHANNA
A1 LISA K. STAMP
A1 FIONA M. McQUEEN
A1 TUHINA NEOGI
A1 ANGELO L. GAFFO
A1 MICHAEL A. BECKER
A1 PATRICIA A. MacDONALD
A1 OMAR DABBOUS
A1 VIBEKE STRAND
A1 NICOLA D. DALBETH
A1 DANIEL ALETAHA
A1 N. LAWRENCE EDWARDS
A1 H. RALPH SCHUMACHER, Jr
YR 2011
UL http://www.jrheum.org/content/38/7/1452.abstract
AB Objective. To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10). Methods. During the OMERACT 10 gout workshop, validation data were presented for key PRO domains including pain [pain by visual analog scale (VAS)], patient global (patient global VAS), activity limitation [Health Assessment Questionnaire-Disability Index (HAQ-DI)], and a disease-specific measure, the Gout Assessment Questionnaire version 2.0 (GAQ v2.0). Data were presented on all 3 aspects of the OMERACT filters of truth, discrimination, and feasibility. One PRO, health-related quality of life measurement with the Medical Outcomes Study Short-form 36 (SF-36), was previously endorsed at OMERACT 9. Results. One measure for each of the 3 PRO of pain, patient global, and activity limitation was endorsed by > 70% of the OMERACT delegates to have appropriate validation data. Specifically, pain measurement by VAS was endorsed by 85%, patient global assessment by VAS by 73%, and activity limitation by HAQ-DI by 71%. GAQ v2.0 received 30% vote and was not endorsed due to several concerns including low internal consistency and lack of familiarity with the measure. More validation studies are needed for this measure. Conclusion. With the endorsement of one measure each for pain, patient global, SF-36, and activity limitation, all 4 PRO for chronic gout have been endorsed. Future validation studies are needed for the disease-specific measure, GAQ v2.0. Validation for PRO for acute gout will be the focus of the next validation exercise for the OMERACT gout group.